Prosensa Awarded Best Biotech Pipeline 2013 At The Rare & Orphan Advocacy And Research (ROAR) Awards

Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutchbiopharmaceutical company focusing on rare diseases with a highunmet medical need, has been awarded Best Biotech Pipeline 2013 inthe Rare & Orphan Advocacy and Research (ROAR) Awards.

The ROAR Awards were announced during the 4thAnnual World Orphan Drug Congress Europe, November 14-15, 2013, inGeneva, Switzerland. The inaugural 2013 awards are an opportunityto recognize and honor achievements by organizations andindividuals from industry, patient, and rare disease advocacycommunities.

"There is a desperate unmet need in rarediseases, and we are dedicated to developing treatments forpatients who face very limited options," said Hans Schikan, CEO ofProsensa. "We are honored to accept this award and would like tothank the judging committee for recognizing our efforts, and ourmany partners and advocates for their steadfast support."

The Best Biotech Pipeline Award recognizes thebreadth and depth of the company's orphan drug pipeline, mostnotably its pioneering work in Duchenne muscular dystrophy,myotonic dystrophy and Huntington's disease.

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engagedin the discovery and development of RNA-modulating therapeutics forthe treatment of genetic disorders. Its primary focus is on rareneuromuscular and neurodegenerative disorders with a large unmetmedical need, including Duchenne muscular dystrophy, myotonicdystrophy and Huntington's disease.

Prosensa's current portfolio includes six compounds for thetreatment of DMD, all of which have received orphan drug status inthe United States and the European Union. The compounds use aninnovative technique called exon-skipping to provide a personalizedmedicine approach to treat different populations of DMD patients.
CONTACT: Prosensa Holding N.V.         Celia Economides, Director IR & Corporate Communications         Phone: +1 917 941 9059         Email:

Prosensa Holding B.V. Logo